View in EDS

Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety.

Saved in:
Bibliographic Details
Title: Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety.
Authors: Chu, Derek K., Wood, Robert A., French, Shannon, Fiocchi, Alessandro, Jordana, Manel, Waserman, Susan, Brożek, Jan L., Schünemann, Holger J.
Source: Lancet. 6/1/2019, Vol. 393 Issue 10187, p2222-2232. 11p.
Subjects: Peanut allergy, Immunotherapy, Allergy desensitization, European Medicines Agency, Meta-analysis, Clinical trial registries, Scientific literature, Anaphylaxis, Medical databases, Evaluation research, Food allergy, Oral drug administration, Systematic reviews, Quality of life, Research methodology, Research, Comparative studies
Abstract: Background: Oral immunotherapy is an emerging experimental treatment for peanut allergy, but its benefits and harms are unclear. We systematically reviewed the efficacy and safety of oral immunotherapy versus allergen avoidance or placebo (no oral immunotherapy) for peanut allergy.Methods: In the Peanut Allergen immunotherapy, Clarifying the Evidence (PACE) systematic review and meta-analysis, we searched MEDLINE, EMBASE, Cochrane Controlled Register of Trials, Latin American & Caribbean Health Sciences Literature, China National Knowledge Infrastructure, WHO's Clinical Trials Registry Platform, US Food and Drug Administration, and European Medicines Agency databases from inception to Dec 6, 2018, for randomised controlled trials comparing oral immunotherapy versus no oral immunotherapy for peanut allergy, without language restrictions. We screened studies, extracted data, and assessed risk of bias independently in duplicate. Main outcomes included anaphylaxis, allergic or adverse reactions, epinephrine use, and quality of life, meta-analysed by random effects. We assessed certainty (quality) of evidence by the GRADE approach. This study is registered with PROSPERO, number CRD42019117930.Results: 12 trials (n=1041; median age across trials 8·7 years [IQR 5·9-11·2]) showed that oral immunotherapy versus no oral immunotherapy increased anaphylaxis risk (risk ratio [RR] 3·12 [95% CI 1·76-5·55], I2=0%, risk difference [RD] 15·1%, high-certainty), anaphylaxis frequency (incidence rate ratio [IRR] 2·72 [1·57-4·72], I2=0%, RD 12·2%, high-certainty), and epinephrine use (RR 2·21 [1·27-3·83], I2=0%, RD 4·5%, high-certainty) similarly during build-up and maintenance (pinteraction=0·92). Oral immunotherapy increased serious adverse events (RR 1·92 [1·00-3·66], I2=0%, RD 5·7%, moderate-certainty), and non-anaphylactic reactions (vomiting: RR 1·79 [95%CI 1·35-2·38], I2=0%, high-certainty; angioedema: 2·25 [1·13-4·47], I2=0%, high-certainty; upper tract respiratory reactions: 1·36 [1·02-1·81], I2=0%, moderate-certainty; lower tract respiratory reactions: 1·55 [0·96-2·50], I2=28%, moderate-certainty). Passing a supervised challenge, a surrogate for preventing out-of-clinic reactions, was more likely with oral immunotherapy (RR 12·42 [95% CI 6·82-22·61], I2=0%, RD 36·5%, high-certainty). Quality of life was not different between groups (combined parents and self report RR 1·21 [0·87-1·69], I2=0%, RD 0·03%, low-certainty). Findings were robust to IRR, trial sequential, subgroup, and sensitivity analyses.Interpretation: In patients with peanut allergy, high-certainty evidence shows that available peanut oral immunotherapy regimens considerably increase allergic and anaphylactic reactions over avoidance or placebo, despite effectively inducing desensitisation. Safer peanut allergy treatment approaches and rigorous randomised controlled trials that evaluate patient-important outcomes are needed.Funding: None. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 136896985
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Chu%2C+Derek+K%2E%22">Chu, Derek K.</searchLink><br /><searchLink fieldCode="AR" term="%22Wood%2C+Robert+A%2E%22">Wood, Robert A.</searchLink><br /><searchLink fieldCode="AR" term="%22French%2C+Shannon%22">French, Shannon</searchLink><br /><searchLink fieldCode="AR" term="%22Fiocchi%2C+Alessandro%22">Fiocchi, Alessandro</searchLink><br /><searchLink fieldCode="AR" term="%22Jordana%2C+Manel%22">Jordana, Manel</searchLink><br /><searchLink fieldCode="AR" term="%22Waserman%2C+Susan%22">Waserman, Susan</searchLink><br /><searchLink fieldCode="AR" term="%22Brożek%2C+Jan+L%2E%22">Brożek, Jan L.</searchLink><br /><searchLink fieldCode="AR" term="%22Schünemann%2C+Holger+J%2E%22">Schünemann, Holger J.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 6/1/2019, Vol. 393 Issue 10187, p2222-2232. 11p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Peanut+allergy%22">Peanut allergy</searchLink><br /><searchLink fieldCode="DE" term="%22Immunotherapy%22">Immunotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Allergy+desensitization%22">Allergy desensitization</searchLink><br /><searchLink fieldCode="DE" term="%22European+Medicines+Agency%22">European Medicines Agency</searchLink><br /><searchLink fieldCode="DE" term="%22Meta-analysis%22">Meta-analysis</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trial+registries%22">Clinical trial registries</searchLink><br /><searchLink fieldCode="DE" term="%22Scientific+literature%22">Scientific literature</searchLink><br /><searchLink fieldCode="DE" term="%22Anaphylaxis%22">Anaphylaxis</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+databases%22">Medical databases</searchLink><br /><searchLink fieldCode="DE" term="%22Evaluation+research%22">Evaluation research</searchLink><br /><searchLink fieldCode="DE" term="%22Food+allergy%22">Food allergy</searchLink><br /><searchLink fieldCode="DE" term="%22Oral+drug+administration%22">Oral drug administration</searchLink><br /><searchLink fieldCode="DE" term="%22Systematic+reviews%22">Systematic reviews</searchLink><br /><searchLink fieldCode="DE" term="%22Quality+of+life%22">Quality of life</searchLink><br /><searchLink fieldCode="DE" term="%22Research+methodology%22">Research methodology</searchLink><br /><searchLink fieldCode="DE" term="%22Research%22">Research</searchLink><br /><searchLink fieldCode="DE" term="%22Comparative+studies%22">Comparative studies</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>Oral immunotherapy is an emerging experimental treatment for peanut allergy, but its benefits and harms are unclear. We systematically reviewed the efficacy and safety of oral immunotherapy versus allergen avoidance or placebo (no oral immunotherapy) for peanut allergy.<bold>Methods: </bold>In the Peanut Allergen immunotherapy, Clarifying the Evidence (PACE) systematic review and meta-analysis, we searched MEDLINE, EMBASE, Cochrane Controlled Register of Trials, Latin American & Caribbean Health Sciences Literature, China National Knowledge Infrastructure, WHO's Clinical Trials Registry Platform, US Food and Drug Administration, and European Medicines Agency databases from inception to Dec 6, 2018, for randomised controlled trials comparing oral immunotherapy versus no oral immunotherapy for peanut allergy, without language restrictions. We screened studies, extracted data, and assessed risk of bias independently in duplicate. Main outcomes included anaphylaxis, allergic or adverse reactions, epinephrine use, and quality of life, meta-analysed by random effects. We assessed certainty (quality) of evidence by the GRADE approach. This study is registered with PROSPERO, number CRD42019117930.<bold>Results: </bold>12 trials (n=1041; median age across trials 8·7 years [IQR 5·9-11·2]) showed that oral immunotherapy versus no oral immunotherapy increased anaphylaxis risk (risk ratio [RR] 3·12 [95% CI 1·76-5·55], I2=0%, risk difference [RD] 15·1%, high-certainty), anaphylaxis frequency (incidence rate ratio [IRR] 2·72 [1·57-4·72], I2=0%, RD 12·2%, high-certainty), and epinephrine use (RR 2·21 [1·27-3·83], I2=0%, RD 4·5%, high-certainty) similarly during build-up and maintenance (pinteraction=0·92). Oral immunotherapy increased serious adverse events (RR 1·92 [1·00-3·66], I2=0%, RD 5·7%, moderate-certainty), and non-anaphylactic reactions (vomiting: RR 1·79 [95%CI 1·35-2·38], I2=0%, high-certainty; angioedema: 2·25 [1·13-4·47], I2=0%, high-certainty; upper tract respiratory reactions: 1·36 [1·02-1·81], I2=0%, moderate-certainty; lower tract respiratory reactions: 1·55 [0·96-2·50], I2=28%, moderate-certainty). Passing a supervised challenge, a surrogate for preventing out-of-clinic reactions, was more likely with oral immunotherapy (RR 12·42 [95% CI 6·82-22·61], I2=0%, RD 36·5%, high-certainty). Quality of life was not different between groups (combined parents and self report RR 1·21 [0·87-1·69], I2=0%, RD 0·03%, low-certainty). Findings were robust to IRR, trial sequential, subgroup, and sensitivity analyses.<bold>Interpretation: </bold>In patients with peanut allergy, high-certainty evidence shows that available peanut oral immunotherapy regimens considerably increase allergic and anaphylactic reactions over avoidance or placebo, despite effectively inducing desensitisation. Safer peanut allergy treatment approaches and rigorous randomised controlled trials that evaluate patient-important outcomes are needed.<bold>Funding: </bold>None. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=136896985
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(19)30420-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 2222
    Subjects:
      – SubjectFull: Peanut allergy
        Type: general
      – SubjectFull: Immunotherapy
        Type: general
      – SubjectFull: Allergy desensitization
        Type: general
      – SubjectFull: European Medicines Agency
        Type: general
      – SubjectFull: Meta-analysis
        Type: general
      – SubjectFull: Clinical trial registries
        Type: general
      – SubjectFull: Scientific literature
        Type: general
      – SubjectFull: Anaphylaxis
        Type: general
      – SubjectFull: Medical databases
        Type: general
      – SubjectFull: Evaluation research
        Type: general
      – SubjectFull: Food allergy
        Type: general
      – SubjectFull: Oral drug administration
        Type: general
      – SubjectFull: Systematic reviews
        Type: general
      – SubjectFull: Quality of life
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Comparative studies
        Type: general
    Titles:
      – TitleFull: Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Chu, Derek K.
      – PersonEntity:
          Name:
            NameFull: Wood, Robert A.
      – PersonEntity:
          Name:
            NameFull: French, Shannon
      – PersonEntity:
          Name:
            NameFull: Fiocchi, Alessandro
      – PersonEntity:
          Name:
            NameFull: Jordana, Manel
      – PersonEntity:
          Name:
            NameFull: Waserman, Susan
      – PersonEntity:
          Name:
            NameFull: Brożek, Jan L.
      – PersonEntity:
          Name:
            NameFull: Schünemann, Holger J.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 6/1/2019
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 393
            – Type: issue
              Value: 10187
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1